Abstract
Osteosarcoma is the most common type of primary bone tumor in adolescents and young adults. The dysregulation of cell cycle control and cell division often results in the aberrant growth of osteosarcoma cells. The primary proteins involved in cell cycle control and cell division include checkpoint kinases (CHKs), cyclin-dependent kinases (CDKs), polo-like kinases (PLKs) and aurora kinases (AURKs). In recent years, a large number of these protein kinase inhibitors have been identified in osteosarcoma. In this review, we highlight the current drugs being developed to target these protein kinases in osteosarcoma.
Keywords: Checkpoint kinase inhibitors, cyclin-dependent kinase inhibitors, polo-like kinase inhibitors, aurora kinase inhibitors, cell cycle, osteosarcoma.
Current Pharmaceutical Design
Title:Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention
Volume: 22 Issue: 31
Author(s): Li Cheng, Chongchong Wang and Juehua Jing
Affiliation:
Keywords: Checkpoint kinase inhibitors, cyclin-dependent kinase inhibitors, polo-like kinase inhibitors, aurora kinase inhibitors, cell cycle, osteosarcoma.
Abstract: Osteosarcoma is the most common type of primary bone tumor in adolescents and young adults. The dysregulation of cell cycle control and cell division often results in the aberrant growth of osteosarcoma cells. The primary proteins involved in cell cycle control and cell division include checkpoint kinases (CHKs), cyclin-dependent kinases (CDKs), polo-like kinases (PLKs) and aurora kinases (AURKs). In recent years, a large number of these protein kinase inhibitors have been identified in osteosarcoma. In this review, we highlight the current drugs being developed to target these protein kinases in osteosarcoma.
Export Options
About this article
Cite this article as:
Cheng Li, Wang Chongchong and Jing Juehua, Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention, Current Pharmaceutical Design 2016; 22 (31) . https://dx.doi.org/10.2174/1381612822666160512151028
DOI https://dx.doi.org/10.2174/1381612822666160512151028 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Current Cancer Drug Targets Circular RNA and Diabetes: Epigenetic Regulator with Diagnostic Role
Current Molecular Medicine Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Unraveling Potential Candidate Targets Associated with Expression of p16<sup>INK4a</sup> or p16 Truncated Fragment by Comparative Proteomics Analysis
Current Proteomics Isothymusin, a Potential Inhibitor of Cancer Cell Proliferation: An In Silico and In Vitro Investigation
Current Topics in Medicinal Chemistry Advance in Anti-tumor Mechanisms of Shikonin, Alkannin and their Derivatives
Mini-Reviews in Medicinal Chemistry Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms
Current Neuropharmacology Synthetic Optimization of Ellipticine and Antitumor Activity of Novel Hexacyclic Derivatives of Ellipticine
Current Pharmaceutical Design Synthesis of Novel Imine Stilbene Analogs Exhibiting Potent Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology The Parathyroid Hormone Receptorsome and the Potential for Therapeutic Intervention
Current Drug Targets Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Ewing’s Sarcoma Cancer Stem Cell Targeted Therapy
Current Stem Cell Research & Therapy